Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donanemab in early symptomatic Alzheimer's disease
2020-000077-25Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Donanemab with Placebo (2 arms). Primary endpoint: Primary objective. Started May 2020; status: active.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2020-000077-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000077-25.